• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cel-Sci Corporation

    8/29/25 4:16:51 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CVM alert in real time by email
    S-8 1 cvm_s8.htm FORM S-8 cvm_s8.htm

       

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

      

    FORM S-8

    REGISTRATION STATEMENT

     

    Under the Securities Act of l933

     

    CEL-SCI CORPORATION

    (Exact name of issuer as specified in its charter)

     

    Colorado

     

    84-0916344

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

     

     

    8229 Boone Blvd., Suite 802

    Vienna, Virginia

     

    22182

    (Address of Principal Executive Offices)

     

    (Zip Code)

      

    2025 Non-Qualified Stock Option Plan

    2025 Stock Bonus Plan

     

    _______________________________

    (Full Title of Plan)

     

    Geert R. Kersten

    CEL-SCI Corporation

    8229 Boone Blvd., Suite 802

    Vienna, Virginia 22182

    (Name and address of agent for service)

     

    (703) 506-9460

    (Telephone number, including area code, of agent for service)

     

    Copies of all communications, including all communications sent to agent for service to:

     

    William T. Hart, Esq.

    Hart & Hart

    l624 N. Washington Street

    Denver, Colorado  80203

    (303) 839-0061

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    CEL-SCI CORPORATION

    Cross Reference Sheet Required Pursuant to Rule 404

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    (NOTE:

    Pursuant to instructions to Form S-8, the Prospectus described below is not required to be filed with this Registration Statement.)

     

    Item No.

     

    Form S-8 Caption

     

    Caption in Prospectus

     

     

     

     

     

     

    1.

     

    Plan Information

     

     

     

     

     

     

     

     

     

     

    (a)

    General Plan Information

     

    Stock Option and Bonus Plan

     

     

     

     

     

     

     

     

    (b)

    Securities to be Offered

    Stock Option and Bonus Plan

     

     

     

     

     

     

     

     

    (c)

    Employees who may Participate in the Plans

     

    Stock Option and Bonus Plan

     

     

     

     

     

     

     

     

    (d)

    Purchase of Securities Pursuant to the Plans and Payment for Securities Offered

    Stock Option and Bonus Plan

     

     

     

     

     

     

     

    (e)

    Resale Restrictions

     

    Resale of Shares by Affiliates

     

     

     

     

     

     

     

     

    (f)

    Tax Effects of Plan Participation

    Stock Option and Bonus Plan

     

     

     

     

     

     

     

     

    (g)

    Investment of Funds

     

    Not Applicable.

     

     

     

     

     

     

     

     

    (h)

    Withdrawal from the Plan; Assignment of Interest

    Other Information Regarding the Plans

     

     

     

     

     

     

     

     

    (i)

    Forfeitures and Penalties

     

    Other Information Regarding the Plans

     

     

     

     

     

     

     

     

    (j)

    Charges and Deductions and Liens Therefore

     

    Other Information Regarding the Plans

     

     

     

     

     

     

    2.

     

    Registrant Information and Employee

    Plan Annual Information

     

    Available Information, Documents

    Incorporated by Reference

     

     
    2

     

     

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

     

    Item 3 - Incorporation of Documents by Reference

     

    The following documents filed with the Commission by CEL-SCI (Commission File No. 001-11889) are incorporated by reference into this prospectus:

     

    ·

    our Annual Report on Form 10-K for the fiscal year ended September 30, 2024;

    ·

    our quarterly reports on Form 10-Q for the periods ended December 31, 2024 and March 31, 2025 and June 30, 2025;

    ·

    our current reports on Form 8-K filed with the SEC on November 13, 2024, November 15, 2024, December 31, 2024, March 18, 2025, May 19, 2025, May 23, 2025, July 14, 2025 and August 22, 2025;

    ·

    our Proxy Statement relating to our May 19, 2025 Annual Meeting of Shareholders; and

    ·

    the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on July 2, 1996 and all amendments and reports updating that description.

     

    All documents filed with the Commission by CEL-SCI pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this registration statement and prior to the termination of this offering shall be deemed to be incorporated by reference into this registration statement and to be a part of this registration statement from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained in this registration statement or in any subsequently filed document which also is or is deemed to be incorporated by reference in this registration statement modifies or supersedes such statement. Such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Investors are entitled to rely upon information in this registration statement or incorporated by reference at the time it is used by CEL-SCI to offer and sell securities, even though that information may be superseded or modified by information subsequently incorporated by reference into this registration statement.

     

    Item 4 - Description of Securities

     

    Not required.

     

    Item 5 - Interests of Named Experts and Counsel

     

    Not Applicable.

     

     
    3

     

     

    Item 6 - Indemnification of Directors and Officers

     

    The Bylaws of the Company provide in substance that the Company shall indemnify any person who was or is a party or is threatened to be made a party to any threatened or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative by reason of the fact that such person is or was a director, officer, employee, fiduciary or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee, fiduciary or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney's fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person to the full extent permitted by the laws of the state of Colorado; and that expenses incurred in defending any such civil or criminal action, suit or proceeding may be paid by the Company in advance of the final disposition of such action, suit or proceeding as authorized by the Board of Directors in the specific case upon receipt of an undertaking by or on behalf of such indemnified person to repay such amount to the Company unless it shall ultimately be determined that such person is entitled to be indemnified by the Company as authorized in the Bylaws.

     

    Item 7 – Exemption for Registration Claimed

     

    Not applicable.

     

    Item 8 - Exhibits 

     

    4 -

    Instruments Defining Rights of Security Holders

     

     

     

     

     

     

    (a) -

    Common Stock

     

    Incorporated by reference to Exhibit 4(a) of the Company's Registration Statements on Form S-l, File Nos. 2-85547-D and 33-7531.

     

     

     

     

    (b) -

    2025 Non-Qualified Stock Option Plan

     

     

     

     

     

     

    (c) -

    2025 Stock Bonus Plan

     

     

     

     

     

     

    5 -

    Opinion Regarding Legality

     

     

     

     

     

     

    l5 -

    Letter Regarding Unaudited Interim Financial Information

     

    None

     

     

     

     

    23 -

    Consent of Independent Public Accountants and Attorneys

     

     

     

     

     

     

    24 -

    Power of Attorney

     

    Included in the signature page of this Registration Statement

     

     

     

     

    99 -

    Additional Exhibits

     

    Re-offer Prospectus

     

     

     

     

    107 –

    Filing Fee Table

     

     

     

     
    4

     

     

    Item 9 - Undertakings

     

    (a) The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

     

    (i)

    to include any prospectus required by Section l0(a)(3) of the Securities Act of l933;

     

     

     

     

    (ii)

    to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and

     

     

     

     

    (iii)

    to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change in such information in the registration statement.

     

     

     

     

     

    Provided, however, that paragraphs (a)(l)(i) and (a)(l)(ii) will not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the registrant pursuant to Section l3 or Section l5(d) of the Securities Act of l934.

     

    (2) That, for the purpose of determining any liability under the Securities Act of l933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of l933, each filing of the registrant's Annual Report pursuant to Section l3(a) or Section l5(d) of the Securities Exchange Act of l934 (and, where applicable, each filing of any employee benefit plan's annual report pursuant to Section l5(d) of the Securities Exchange Act of l934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

     

     
    5

     

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned constitutes and appoints Geert R. Kersten, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitutes or substitute may lawfully do or cause to be done by virtue hereof.

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of l933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Vienna, Virginia, on August 29, 2025.

     

     

    CEL-SCI CORPORATION

     

     

     

     

     

     

    By:

    /s/Geert R. Kersten 

     

     

     

    Geert R. Kersten, Principal Executive and Accounting Officer

     

     

     

     

     

     

    By:

    /s/Patricia Prichep

     

     

     

    Patricia Prichep, Principal Financial and Operations Officer

     

     

    Pursuant to the requirements of the Securities Act of l933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

    Title

     

    Date

     

     

     

     

     

    /s/Geert R. Kersten

     

    Director,

     

    August 29, 2025

    Geert R. Kersten

     

     

     

     

     

     

     

     

     

    /s/Robert Watson

     

    Director

     

    August 29, 2025

    Robert Watson

     

     

     

     

     

     

     

    /s/Bruno Baillavoine

     

    Director, Chairman of the Board

     

    August 29, 2025

    Bruno Baillavoine

     

     

     

     

     
    6

     

     

    FORM S-8

     

    CEL-SCI Corporation

    8229 Boone Blvd.

    Suite 802

    Vienna, Virginia 22182

     

    EXHIBITS

     

     
    7

     

    Get the next $CVM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Watson Robert Eugene

    4 - CEL SCI CORP (0000725363) (Issuer)

    7/29/25 5:20:52 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Baillavoine Bruno Jean-Marie

    4 - CEL SCI CORP (0000725363) (Issuer)

    7/29/25 5:15:08 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Senior Vice President Cipriano John

    4 - CEL SCI CORP (0000725363) (Issuer)

    7/29/25 5:12:13 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    SEC Filings

    View All

    SEC Form S-8 filed by Cel-Sci Corporation

    S-8 - CEL SCI CORP (0000725363) (Filer)

    8/29/25 4:16:51 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cel-Sci Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - CEL SCI CORP (0000725363) (Filer)

    8/29/25 1:15:44 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Cel-Sci Corporation

    424B5 - CEL SCI CORP (0000725363) (Filer)

    8/28/25 4:24:34 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CEL-SCI Announces Closing of $10 Million Public Offering

    CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its offering of 1,111,200 shares of its common stock. Each share of common stock was sold at a public offering price of $9.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $10 million. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offering. The securities were offered and sold pursuant to

    8/29/25 12:52:00 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Announces Pricing of $10 Million Public Offering

    CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock. Each share of common stock is being sold at a public offering price of $9.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $10 million. The offering is expected to close on August 29, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate

    8/27/25 10:35:00 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Announces Proposed Public Offering

    CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) in a best-efforts public offering. All of the shares of common stock (and/or Pre-Funded Warrants) are being offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from this offering to fund the continued development of Multikine*, for general corporate

    8/27/25 5:25:00 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Watson Robert Eugene bought $19,995 worth of shares (2,919 units at $6.85), increasing direct ownership by 359% to 3,733 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    7/29/25 7:56:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kersten Geert R bought $199,999 worth of shares (29,197 units at $6.85), increasing direct ownership by 67% to 72,835 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    7/28/25 9:36:31 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Watson Robert Eugene bought $27,800 worth of shares (20,000 units at $1.39), increasing direct ownership by 451% to 24,431 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    5/10/24 9:04:18 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

    SC 13G/A - CEL SCI CORP (0000725363) (Subject)

    2/8/23 10:48:28 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

    SC 13G/A - CEL SCI CORP (0000725363) (Subject)

    4/11/22 1:55:14 PM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cel-Sci Corporation (Amendment)

    SC 13G/A - CEL SCI CORP (0000725363) (Subject)

    2/11/22 7:53:04 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CVM
    Leadership Updates

    Live Leadership Updates

    View All

    CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

    CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This

    8/15/24 8:00:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Appoints Robert Watson as Chairperson of the Board

    CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in

    7/8/24 9:15:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEL-SCI Appoints Mario Gobbo to Its Board of Directors

    CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation

    4/23/24 9:00:00 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care